Purchase this article with an account.
Yoshihiro Mizutani, Kyoko Fujita, Kei Shinoda, Yutaka Imamura, Soiti C. Matsumoto, Mitsuko Yuzawa; Metamorphopsia in Eyes with Chronic Central Serous Chorioretinopathy; One year after Half-dose Verteporfin Photodynamic Therapy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5224.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate metamorphopsia 1 year after half-dose verteporfin photodynamic therapy (PDT) in eyes with chronic central serous chorioretinopathy (CSC).
Thirty-five eyes (35 patients; average age, 54.5 years) with chronic CSC were evaluated. Metamorphopsia with horizontal line and vertical line were examined using M-CHARTS before and at 12 months after half dose verteporfin PDT. In this study, a change in the metamorphopsia score greater than 0.2 was considered as a positive detection. Main outcome measure was improvement in metamorphopsia at 12 months.
Thirty-two of 35 eyes showed a complete resolution of retinal detachment at 1 month, and at 6 months in 2 eyes, whereas 1 eye showed persistent serous retinal detachment throughout the follow-up period. At 12 months, the horizontal metamorphopsia score improved more than 0.2 degrees from the baseline in 15 of 35 eyes and worsened more than 0.2 degrees in 4 of 35 eyes. The vertical metamorphopsia score improved more than 0.2 degrees in 18 of 35 eyes and worsened more than 0.2 degrees in 5 of 35 eyes. The mean horizontal metamorphopsia score did not significantly improve from 0.6 ± 0.5 degrees at baseline to 0.4 ± 0.6 degrees at 12 months (p = 0.11). The mean vertical metamorphopsia score significantly improved from 0.5 ±0.5 degrees at baseline to 0.3 ± 0.5 degrees at 12 month (p = 0.04). In the eyes with visual acuity (VA) ≥ 1.0 at baseline, the mean horizontal and vertical metamorphosia scores at 12 months were significantly improved from baseline (p < 0.05), whereas in eyes with VA < 1.0 at baseline those scores did not improve from baseline (p < 0.05).
Half-dose verteporfin PDT for chronic CSC resulted in improvement of vertical metamorphopsia in 1 year. The improvement was significant in eyes with VA ≥ 1.0 but not significant in eyes with VA < 1.0. Therefore the half-dose verteporfin PDT may profit if considered before decreasing of VA.
This PDF is available to Subscribers Only